Emerging as a major global health concern, metabolic dysfunction-associated steatohepatitis (MASH) is closely linked to obesity, type 2 diabetes, and other metabolic disorders. Advances in metabolic research have positioned glucagon-like peptide-1 receptor agonists (GLP-1 RAs) as a promising therapeutic option for MASH, extending their use beyond diabetes and obesity management. In our latest article, WuXi Biology examines the potential of GLP-1 RAs in MASH treatment, exploring their mechanisms of action, clinical benefits, developmental challenges, and evaluation strategies in preclinical MASH models. Click 👇 to view our case study and learn about our platform of liver disease models: https://lnkd.in/gECfTmD9 #Biotech #DrugDiscovery #MASH #NASH #NAFLD #GLP1 #Fibrosis #Cirrhosis
